Le Lézard
Classified in: Health, Science and technology, Business, Covid-19 virus
Subjects: EARNINGS, Conference Call, Webcast

Seagen Reports Second Quarter 2021 Financial Results


Seagen Inc. (Nasdaq:SGEN) today reported financial results for the second quarter and six months ended June 30, 2021. The Company also highlighted ADCETRIS® (brentuximab vedotin), PADCEV® (enfortumab vedotin-ejfv) and TUKYSA® (tucatinib) commercial and development accomplishments, as well as progress across its robust oncology pipeline.

"The commercial execution across our three brands continues to be strong, achieving record quarterly net product sales for each of ADCETRIS, PADCEV and TUKYSA, as we bring these important medicines to patients around the world," said Clay Siegall, Ph.D., President and Chief Executive Officer of Seagen. "We are investing in clinical trials to maximize the potential of our three approved drugs, and making strong progress with TUKYSA commercialization in the European Union. Looking ahead to the remainder of 2021, Seagen is poised to add a fourth product, tisotumab vedotin, which has an FDA action date in October 2021 and we expect continued progress across our earlier-stage oncology pipeline with planned clinical data presentations and other development accomplishments."

PROGRAM HIGHLIGHTS

PADCEV

TUKYSA

ADCETRIS

Tisotumab Vedotin

For additional information on Seagen's pipeline, visit www.seagen.com/science/pipeline.

SECOND QUARTER AND SIX-MONTHS 2021 FINANCIAL RESULTS

Revenues: Total revenues for the second quarter and six months ended June 30, 2021 increased to $388.5 million and $720.5 million, respectively, compared to $278.0 million and $512.5 million for the same periods in 2020. Growth over 2020 was primarily driven by higher sales of PADCEV and the addition of TUKYSA to the Company's commercial portfolio. Revenues are composed of the following three components:

Three months ended June 30,

 

Six months ended June 30,

(dollars in millions)

2021

 

2020

% Change

 

2021

 

2020

% Change

Total Net Product Sales

$

347.3

 

 

$

240.5

 

44%

 

$

649.9

 

 

$

439.0

 

48%

ADCETRIS

181.9

 

 

167.5

 

9%

 

344.5

 

 

331.6

 

4%

PADCEV

82.4

 

 

57.2

 

44%

 

152.2

 

 

91.6

 

66%

TUKYSA

83.0

 

 

15.8

 

427%

 

153.3

 

 

15.8

 

873%

Note: Sum of product sales may not equal total net product sales due to rounding.

Cost of Sales: Cost of sales for the second quarter and year-to-date in 2021 were $78.1 million and $142.2 million, respectively, compared to $48.2 million and $77.7 million for the same periods in 2020. The increase was primarily due to the PADCEV gross profit share with Astellas, which was $38.6 million and $71.1 million in the second quarter and year-to-date of 2021, respectively, compared to $27.1 million and $43.5 million for the same periods in 2020. The increase in cost of sales also reflected amortization of acquired in-process technology costs that began with the approval of TUKYSA in April 2020, and third-party royalties owed for ADCETRIS, PADCEV and TUKYSA net product sales, in addition to cost of products sold.

Research and Development (R&D) Expenses: R&D expenses for the second quarter and year-to-date in 2021 were $234.9 million and $465.3 million, respectively, compared to $198.1 million and $393.3 million for the same periods in 2020. The increase in 2021 primarily reflected continued investment in clinical development of the Company's approved drugs and to advance novel programs and technologies.

Selling, General and Administrative (SG&A) Expenses: SG&A expenses for the second quarter and year-to-date in 2021 were $165.1 million and $325.0 million, respectively, compared to $125.6 million and $247.9 million for the same periods in 2020. The increases in 2021 primarily reflected investments to support European TUKYSA launches and our global expansion efforts.

Non-cash, share-based compensation expense for the first six months of 2021 was $76.0 million, compared to $68.4 million for the same period in 2020.

Net Loss: Net loss for the second quarter of 2021 was $84.6 million, or $0.47 per diluted share, compared to net loss of $21.2 million, or $0.12 per diluted share, for the second quarter of 2020. Net loss for the six months ended June 30, 2021 was $206.0 million, or $1.14 per diluted share, compared to net loss of $189.6 million, or $1.10 per diluted share, for the same period in 2020.

Cash and Investments: As of June 30, 2021, Seagen had $2.5 billion in cash and investments.

2021 FINANCIAL OUTLOOK

Seagen anticipates 2021 revenues, operating expenses and other costs to be in the ranges shown in the table below, unchanged from the Company's previous financial guidance provided on February 11, 2021.

Revenues

ADCETRIS net product sales

$675 million to $700 million

PADCEV net product sales

$310 million to $325 million

TUKYSA net product sales

$300 million to $315 million

Royalty revenues

$125 million to $135 million

Collaboration and license agreement revenues

Less than $20 million

Operating expenses and other costs

Cost of Sales

$270 million to $300 million

R&D expenses

$900 million to $1,000 million

SG&A expenses

$650 million to $725 million

Non-cash expenses1 (primarily attributable to share-based compensation)

$225 million to $245 million

1. Non-cash expenses include share-based compensation, depreciation and amortization of intangible assets.

Conference Call Details

Seagen management will host a conference call and webcast with supporting slides to discuss its second quarter 2021 and year-to-date financial results and provide an update on business activities. The event will be held today at 1:30 p.m. Pacific Time (PT); 4:30 p.m. Eastern Time (ET). The live event will be simultaneously webcast and available for replay from the Seagen website at www.seagen.com, under the Investors section. Investors may also participate in the conference call by calling 844-763-8274 (domestic) or 412-717-9224 (international). The conference ID is 10157814. Supporting slides are available on the Seagen website at www.seagen.com under the Investors section. A webcast replay will be archived on the Company's website www.seagen.com, under the Investors section.

About Seagen

Seagen Inc. is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a meaningful difference in people's lives. Seagen is headquartered in the Seattle, Washington area, and has locations in California, Canada, Switzerland and the European Union. For more information on our marketed products and robust pipeline, visit www.seagen.com and follow @SeagenGlobal on Twitter.

Forward-Looking Statements

Certain of the statements made in this press release are forward looking, such as those, among others, relating to the Company's 2021 outlook, including anticipated 2021 revenues, costs and expenses; the Company's potential to achieve the noted development and regulatory milestones in 2021 and in future periods; the Company's pipeline; anticipated activities related to the Company's planned and ongoing clinical trials; the potential for the Company's clinical trials to support further development, regulatory submissions and potential marketing approvals in the U.S. and in other countries; the opportunities for, and the therapeutic and commercial potential of ADCETRIS, PADCEV, TUKYSA, tisotumab vedotin and ladiratuzumab vedotin and the Company's other product candidates and those of its licensees and collaborators; anticipated progress with respect to commercialization of TUKYSA in the European Union; the potential to achieve regulatory approvals for, or to commercialize, tisotumab vedotin; the timeline for completing enrollment in randomized cohort K of the EV-103 trial; the potential for data from the EV-103 trial to support registration under the FDA's accelerated approval pathway; the Company's global expansion; potential future milestone payments and royalties under the Company's collaborations; as well as other statements that are not historical fact. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include without limitation: the risks that the Company's ADCETRIS, PADCEV and TUKYSA net sales, revenues, expenses, costs, and other financial guidance may not be as expected; risks and uncertainties associated with maintaining or increasing sales of ADCETRIS, PADCEV and TUKYSA due to competition, unexpected adverse events, regulatory action, reimbursement, market adoption by physicians, impacts associated with COVID-19 or other factors; the risk that the Company or its collaborators may be delayed or unsuccessful in planned clinical trial initiations, enrollment in and conduct of clinical trials, obtaining data from clinical trials, planned regulatory submissions, and regulatory approvals in the U.S. and in other countries in each case for a variety of reasons including the difficulty and uncertainty of pharmaceutical product development, negative or disappointing clinical trial results, unexpected adverse events or regulatory actions and the inherent uncertainty associated with the regulatory approval process; the possibility that the Company may encounter challenges in commercializing its therapeutic agents, including with respect to reimbursement, compliance, operational or other matters; risks relating to the Company's collaboration agreements and its ability to achieve progress dependent milestones thereunder; and risks related to the duration and severity of the COVID-19 pandemic and resulting global economic, financial and healthcare system disruptions. More information about the risks and uncertainties faced by the Company is contained under the caption "Risk Factors" included in the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2021 and the Company's subsequent periodic reports filed with the Securities and Exchange Commission. Seagen disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise except as required by applicable law.

Seagen Inc.

Condensed Consolidated Statements of Operations

(Unaudited)

(In thousands, except per share amounts)

 

 

Three Months Ended June 30,

 

Six Months Ended June 30,

 

2021

 

2020

 

2021

 

2020

Revenues:

 

 

 

 

 

 

 

Net product sales

$

347,338

 

 

$

240,465

 

 

$

649,926

 

 

$

438,979

 

Royalty revenues

36,296

 

 

31,235

 

 

63,514

 

 

51,595

 

Collaboration and license agreement revenues

4,844

 

 

6,298

 

 

7,020

 

 

21,938

 

Total revenues

388,478

 

 

277,998

 

 

720,460

 

 

512,512

 

Costs and expenses:

 

 

 

 

 

 

 

Cost of sales

78,090

 

 

48,244

 

 

142,225

 

 

77,665

 

Research and development

234,861

 

 

198,077

 

 

465,286

 

 

393,276

 

Selling, general and administrative

165,130

 

 

125,642

 

 

324,972

 

 

247,891

 

Total costs and expenses

478,081

 

 

371,963

 

 

932,483

 

 

718,832

 

Loss from operations

(89,603

)

 

(93,965

)

 

(212,023

)

 

(206,320

)

Investment and other income, net

5,027

 

 

72,775

 

 

6,027

 

 

16,728

 

Net loss

$

(84,576

)

 

$

(21,190

)

 

$

(205,996

)

 

$

(189,592

)

Net loss per share - basic and diluted

$

(0.47

)

 

$

(0.12

)

 

$

(1.14

)

 

$

(1.10

)

Shares used in computation of per share amounts - basic and diluted

181,628

 

 

173,406

 

 

181,390

 

 

172,878

 

Seagen Inc.

Condensed Consolidated Balance Sheets

(Unaudited)

(In thousands)

 

 

June 30, 2021

 

December 31, 2020

Assets

 

 

 

Cash, cash equivalents and investments

$

2,451,612

 

$

2,660,250

Other assets

 

1,500,546

 

 

1,340,656

Total assets

$

3,952,158

 

$

4,000,906

Liabilities and Stockholders' Equity

 

 

 

Accounts payable and accrued liabilities

$

433,834

 

$

388,138

Long-term liabilities

 

127,050

 

 

124,668

Stockholders' equity

 

3,391,274

 

 

3,488,100

Total liabilities and stockholders' equity

$

3,952,158

 

$

4,000,906

 


These press releases may also interest you

at 12:27
UL, the global safety science leader, announced that it will open an expanded electromagnetic compatibility (EMC) and wireless laboratory in Carugate, Italy, in October. The enhanced facility will feature an end-to-end service...

at 12:22
Today Whatnot, the live stream shopping platform and marketplace for collectors and enthusiasts, announced that it has raised $150M in Series C from returning investors Andreessen Horowitz, YC Continuity, and new investor CapitalG. They join angel...

at 12:21
For the second year in a row MittGroup has been selected for the Houston Business Journal's Best Places to Work for 2021. MittGroup is a residential and commercial solar company based out of Texas that services customers across the United States. In...

at 12:21
Contentful, the leading content platform for digital experiences, today announced it has been identified as a leader in the Aragon Research Globetm for Content Experience Platforms, 2021i report by Aragon Research, Inc. The Aragon Research Globe is a...

at 12:17
Cherre, the industry's leading real estate data and analytics platform, today announced availability of "Cherre Lightning Connections," datasets from the company's growing Connections Catalog that customers can add to their Cherre data warehouse in...

at 12:15
Onbe, a fast-growing corporate disbursements platform with over 25 years of payments experience counting 11 of the world's leading automotive brands as clients, released a new U.S. study closely examining consumer automotive shopping behaviors....



News published on 29 july 2021 at 16:05 and distributed by: